Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation.

Babić Z, Crkvenčić M, Rajić Z, Mikecin AM, Kralj M, Balzarini J, Petrova M, Vanderleyden J, Zorc B.

Molecules. 2012 Jan 23;17(1):1124-37. doi: 10.3390/molecules17011124.

2.

Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.

Li W, Zhai X, Zhong Z, Li G, Pu Y, Gong P.

Arch Pharm (Weinheim). 2011 Jun;344(6):349-57. doi: 10.1002/ardp.201000326. Epub 2011 Mar 24.

PMID:
21433057
3.

Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.

El-Gamal MI, Jung MH, Lee WS, Sim T, Yoo KH, Oh CH.

Eur J Med Chem. 2011 Aug;46(8):3218-26. doi: 10.1016/j.ejmech.2011.04.031. Epub 2011 Apr 16.

PMID:
21592628
4.

Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents.

Yao J, Chen J, He Z, Sun W, Xu W.

Bioorg Med Chem. 2012 May 1;20(9):2923-9. doi: 10.1016/j.bmc.2012.03.018. Epub 2012 Mar 14.

PMID:
22483592
5.

Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma.

Kim HJ, Jung MH, Kim H, El-Gamal MI, Sim TB, Lee SH, Hong JH, Hah JM, Cho JH, Choi JH, Yoo KH, Oh CH.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):413-7. doi: 10.1016/j.bmcl.2009.08.005. Epub 2009 Aug 6.

PMID:
19897366
6.

Synthesis and antiproliferative evaluation of some new amidino-substituted bis-benzothiazolyl-pyridines and pyrazine.

Racané L, Kraljević Pavelić S, Ratkaj I, Stepanić V, Pavelić K, Tralić-Kulenović V, Karminski-Zamola G.

Eur J Med Chem. 2012 Sep;55:108-16. doi: 10.1016/j.ejmech.2012.07.005. Epub 2012 Jul 15.

PMID:
22841279
7.

New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.

Park JH, El-Gamal MI, Lee YS, Oh CH.

Eur J Med Chem. 2011 Dec;46(12):5769-77. doi: 10.1016/j.ejmech.2011.08.024. Epub 2011 Aug 23.

PMID:
22033063
9.

Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line.

El-Gamal MI, Choi HS, Cho HG, Hong JH, Yoo KH, Oh CH.

Arch Pharm (Weinheim). 2011 Nov;344(11):745-54. doi: 10.1002/ardp.201000375. Epub 2011 Sep 27.

PMID:
21954060
10.

Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.

Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S.

Bioorg Med Chem. 2008 May 1;16(9):4932-53. doi: 10.1016/j.bmc.2008.03.034. Epub 2008 Mar 17.

PMID:
18439832
11.

Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.

Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.

J Gastroenterol. 2011 Jun;46(6):779-89. doi: 10.1007/s00535-011-0380-3. Epub 2011 Feb 18.

PMID:
21331764
12.

Synthesis and antiproliferative activity of some N-sulphonated-2-substituted benzimidazoles and imidazo[4,5-b]pyridines.

Garuti L, Varoli L, Cermelli C, Baggio G, Lupo L, Malagoli M, Castelli M.

Anticancer Drug Des. 1998 Dec;13(8):969-80.

PMID:
10335270
13.

Synthesis and antiproliferative activity in vitro of new pyrido[1,4-b]diazepine derivatives and imidazo[4,5-b]pyridine.

Liszkiewicz H, Nawrocka WP, Sztuba B, Wietrzyk J, Jaroszewicz J, Nasulewicz A, Pełczyńska M.

Acta Pol Pharm. 2011 May-Jun;68(3):349-55.

14.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
15.

Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer.

Ravikumar K, Sridhar B, Bhujanga Rao AK, Pulla Reddy M.

Acta Crystallogr C. 2011 Jan;67(Pt 1):o29-32. doi: 10.1107/S0108270110047451. Epub 2010 Dec 8.

PMID:
21206080
16.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

17.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.

J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.

PMID:
19910069
18.

5-Substituted [1]pyrindine derivatives with antiproliferative activity.

Kolb S, Goddard ML, Loukaci A, Mondésert O, Ducommun B, Braud E, Garbay C.

Eur J Med Chem. 2010 Mar;45(3):896-901. doi: 10.1016/j.ejmech.2009.11.028. Epub 2009 Dec 6.

PMID:
19969400
19.

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.

Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Eto M, Inokuchi J, Kuroiwa K, Kiyoshima K, Naito S.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1557-64. doi: 10.1007/s00280-011-1660-6. Epub 2011 May 5.

PMID:
21544629
20.

Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.

Bolognese A, Correale G, Manfra M, Lavecchia A, Mazzoni O, Novellino E, La Colla P, Sanna G, Loddo R.

J Med Chem. 2004 Feb 12;47(4):849-58.

PMID:
14761187

Supplemental Content

Support Center